Phase 2 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had a blood test showing positive results linked to lupus (called ANA and/or anti-dsDNA tests).
- You have been diagnosed with a specific type of kidney inflammation caused by lupus (called lupus nephritis Class III or IV, with or without Class V), confirmed by a kidney biopsy taken within the last 3 months.
- Your kidney disease is currently active and your doctor has decided you need to start treatment with steroids combined with a specific medication (MMF/MPS).
- Your kidneys are still functioning at a reasonable level, based on a blood test measuring kidney function (eGFR of 30 or above).
- You have received vaccines to protect against certain bacterial infections (Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae).
- You are already receiving appropriate supportive care, which may include anti-malarial tablets (like hydroxychloroquine) and/or blood pressure medications (ACEi or ARB), unless these are not suitable for you.
- This is either your first time being diagnosed with lupus nephritis, or you are experiencing a flare-up of a previous diagnosis.
Who may not be able to join:
- You have received a strong chemotherapy-type treatment called cyclophosphamide for lupus in the last 3 months, or a type of medication called calcineurin inhibitors in the last 3 months before joining.
- Your kidney function has dropped very rapidly (by 50% or more) in the last 3 months, which indicates a severe form of kidney disease.
- Your kidney biopsy shows significant permanent scarring (more than 50%), or your doctor believes your kidneys are unlikely to respond to immune-suppressing treatment.
- You are currently taking steroid tablets (more than 5 mg/day of prednisone or equivalent) for a condition other than lupus, such as asthma or inflammatory bowel disease.
- You have been taking relatively high doses of steroid tablets for lupus recently — specifically more than an average of 15 mg/day over the past 4 weeks, or more than 30 mg/day over the past week.
- You have received more than a total of 1,000 mg of high-dose steroid given through a drip (IV) in the 2 weeks before joining the trial.
- There may be additional criteria not listed here that could affect your eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.